ERAS: Erasca Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for ERAS
Across the 7 sessions after earlier ERAS headlines, the stock closed higher 4 times and lower 3 times, with a median move of 4.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ERAS | SPY |
|---|---|---|---|
| Jan 12, 2026 | Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | -7.8% | +0.2% |
| Jan 7, 2026 | Piper Sandler initiated coverage on Erasca with a new price target | +42.4% | -0.3% |
| Jan 6, 2026 | Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference | +4.0% | +0.6% |
| Nov 25, 2025 | Erasca to Present at the 8th Annual Evercore Healthcare Conference | +6.2% | +0.9% |
| Nov 13, 2025 | Erasca Reports Third Quarter 2025 Business Updates and Financial Results | -4.2% | -1.7% |
| Nov 6, 2025 | Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 | +1.8% | -1.1% |
Quantisnow market dataNASDAQ
ERAS
Erasca Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for ERAS
Full ERAS profile on Quantisnow Follow ERAS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time